Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 608

1.

Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R.

Arch Intern Med. 1997 Jun 9;157(11):1249-55.

PMID:
9183237
2.

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.

Anderson JH Jr, Brunelle RL, Koivisto VA, Pfützner A, Trautmann ME, Vignati L, DiMarchi R.

Diabetes. 1997 Feb;46(2):265-70.

PMID:
9000704
5.

Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.

Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R.

Clin Ther. 1997 Jan-Feb;19(1):62-72.

PMID:
9083709
6.

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD.

Diabetes Care. 1997 Oct;20(10):1539-42.

PMID:
9314631
7.

Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.

Holcombe JH, Zalani S, Arora VK, Mast CJ; Lispro in Adolescents Study Group..

Clin Ther. 2002 Apr;24(4):629-38.

PMID:
12017407
8.
9.

Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.

Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R.

Diabetes Care. 1999 May;22(5):784-8.

10.

Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.

Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group..

Clin Ther. 2004 Dec;26(12):2034-44. Erratum in: Clin Ther. 2005 Jul;27(7):1112.

PMID:
15823767
11.

Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.

Ahmed AB, Mallias J, Home PD.

Diabetes Care. 1998 Jul;21(7):1162-6.

PMID:
9653613
12.

Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.

Pfützner A, Küstner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, Schatz H, Beyer J.

Exp Clin Endocrinol Diabetes. 1996;104(1):25-30.

PMID:
8750567
13.
14.

Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group.

Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH.

Diabetes Care. 1997 Dec;20(12):1827-32.

PMID:
9405901
15.
16.
17.

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.

Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB.

Diabetes Care. 1999 Mar;22(3):468-77.

18.

Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.

Ahmed AB, Home PD.

Diabetes Care. 1998 Oct;21(10):1707-13.

PMID:
9773735
20.

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.

Clin Ther. 2000 Feb;22(2):222-30.

PMID:
10743981

Supplemental Content

Support Center